Table 2.
Initial PET scan (n=111) | Follow-up PET scan (n=89) | |
---|---|---|
Indication for PET scan | ||
+TG with negative 131I scan | 44 (39.6%) | 8 (8.9%) |
TG antibodies | 9 (8.1%) | 4 (4.5%) |
Rising TG | 5 (4.5%) | 13 (14.6%) |
Abnormality on other imaging test | 19 (17.2%) | 3 (3.4%) |
Evaluation of extent of disease | 30 (27.0%) | 3 (3.4%) |
Follow-up of previous PET | N/A | 57 (64.0%) |
Other | 1 (0.9%) | 1 (1.1%) |
Unknown | 3 (2.7%) | 0 (0.0%) |
Method of stimulation | ||
rhTSH | 46 (41.4%) | 51 (57.3%) |
Hypothyroid | 17 (15.3%) | 4 (4.5%) |
Unstimulated | 35 (31.5%) | 64 (32.5%) |
Unknown | 13 (11.7%) | 5 (5.6%) |
PET positive vs. negative | ||
Negative | 40 (36.0%) | 36 (40.5%) |
Positive | 71 (64.0%) | 53 (59.5%) |
Location of abnormality* | ||
Thyroid bed | 18 | 7 |
Neck | 59 | 46 |
Lung | 11 | 17 |
Bone | 2 | 2 |
Other | 8 | 6 |
Abnormality present on other imaging | ||
Yes | 53 (74.6%) | 29 (54.7%) |
No | 8 (11.3%) | 8 (15.1%) |
Unknown | 10 (14.1%) | 16 (30.2%) |
Management following PET | ||
Surgery | 50 (45.0%) | 16 (18.0%) |
Chemo or radiation (includes 131I) | 9 (8.1%) | 14 (15.7%) |
Observation | 52 (46.8%) | 58 (65.2%) |
Palliation | 0 (0%) | 1 (1.1%) |
PET changed management** | ||
Yes | 34 (30.6%) | 25 (28.1%) |
No | 76 (68.5%) | 138 (69.6%) |
Unclear | 1 (0.9%) | 2 (2.2%) |
Patient may have disease in more than one location.
PET was considered to have changed management if it identified disease that was not previously identified and resulted in an intervention, led to cancelation of a previously planned intervention, or changed the extent of a previously planned surgery.
TG, thyroglobulin; rhTSH, recombinant human thyrotropin.